| Patent application number | Description | Published |
|---|
| 20110071213 | CARD-DOMAIN CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE - The invention provides caspase recruitment domain (CARD)-containing polypeptides and functional fragments thereof, encoding nucleic acid molecules, and specific antibodies. Also provided are screening methods for identifying CARD-associated polypeptides (CAPs), and for identifying agents that alter the association of a CARD-containing polypeptide with itself or with a CAP. Further provided are methods of altering a biochemical process modulated by a CARD-containing polypeptide, and methods of diagnosing a pathology characterized by an increased or decreased level of a CARD-containing polypeptide. | 03-24-2011 |
| 20110111057 | Methods and Compounds Useful to Induce Apoptosis in Cancer Cells - The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative. | 05-12-2011 |
| 20110189711 | PAAD DOMAIN-CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE - The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NACHT domains and ARED domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NFκB activity, or modulate an activity of a NACHT domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NFκB transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell. | 08-04-2011 |
| 20110190168 | APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME - A novel human member of the Bcl-2 family Bcl-B has been identified, which is Closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is Widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2, BCl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family. | 08-04-2011 |
| Patent application number | Description | Published |
|---|
| 20080206287 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands - Cyclosporin A has been discovered to sensitize cancers resistant to TNF-family death receptors such as TRAIL and Fas to ligand-mediated apoptosis. Therefore, compositions that include cyclosporin A are useful in treating such cancers. | 08-28-2008 |
| 20080227098 | METHOD FOR DIAGNOSING CANCER OF THE PROSTATE - Methods for diagnosis and prognosis of prostate cancer are provided. The methods involve the detection of the level of expression of Claudin-1 in tissue or cell samples. Claudin-1 is underexpressed or non-expressed in the majority of prostate cancers. | 09-18-2008 |
| 20090105319 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS - Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: | 04-23-2009 |
| 20090163577 | METHODS AND COMPOSITIONS FOR ANTAGONIZING ANTI-APOPTOTIC Bcl-2-FAMILY PROTEINS - The cytotoxic natural product gambogic acid (GA) competes for BH3 peptide binding sites on several anti-apoptotic members of the Bcl-2 family of proteins and neutralizes the ability of these proteins to suppress release of apoptogenic proteins from isolated mitochondria. Structure-function analysis of GA using analogs suggested a general correlation between BH3 competition and cytoxicity activity. Compositions and methods are provided for using GA and its derivatives for treating cancer and for discovering other compounds that are useful for treating cancer through their interaction with Bcl-2-family proteins. | 06-25-2009 |
| 20090181005 | NUCLEIC ACID ENCODING PROTEINS INVOLVED IN PROTEIN DEGRADATION, PRODUCTS AND METHODS RELATED THERETO - In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPS) and/or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and/or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and/or SCP antibodies thereto, in therapeutic compositions, and methods employing such proteins and/or antibodies for drug screening, functional genomics and other applications. Also provided are transgenic non-human mammals that express the invention protein. Also provided are compositions and methods for targeting the destruction of selected polypeptides in eukaryotic cells based on the ubiquitin-independent mechanism by which ornithine decarboxylase is degraded by the 26S proteasome. | 07-16-2009 |
| 20090247520 | INHIBITORS OF ANTIGEN RECEPTOR-INDUCED NF-kappa B ACTIVATION - A method to identify selective inhibitors of antigen receptor-mediated NF-κB activation is provided, as well as compositions having one or more of those inhibitors and methods of using those inhibitors. | 10-01-2009 |
| Patent application number | Description | Published |
|---|
| 20080254510 | NUCLEIC ACID ENCODING PROTEINS INVOLVED IN PROTEIN DEGRADATION, PRODUCTS AND METHODS RELATED THERETO - In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPs) and/or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and/or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and/or SCP antibodies thereto, in therapeutic compositions, and methods employing such proteins and/or antibodies for drug screening, functional genomics and other applications. Also provided are transgenic non-human mammals that express the invention protein. | 10-16-2008 |
| 20090011501 | NOVEL DEATH DOMAIN PROTEINS - In accordance with the present invention, there are provided novel Death Domain (DD), Death Effector Domain (DED) and NB-ARC domain proteins. The invention also provides nucleic acid molecules encoding DD, DED and NB-ARC domain proteins, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention DDs, DEDs or NB-ARC domains. Such DDs, DEDs and NB-ARC domains and/or anti-DD, anti-DED or anti-NB-ARC domain antibodies are useful for discovery of drugs that suppress infection, autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases. | 01-08-2009 |
| 20110183358 | METHODS AND COMPOSITIONS FOR DEREPRESSION OF IAP-INHIBITED CASPASE - The invention provides isolated agents having novel chemical structures and possessing superior activity as derepressors of IAP inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The invention further provides assay methods employing labeled compounds of the invention, especially fluorescent labeled compounds. | 07-28-2011 |
| 20110201780 | NOVEL DEATH DOMAIN PROTEINS - In accordance with the present invention, there are provided novel Death Domain (DD), Death Effector Domain (DED) and NB-ARC domain proteins. The invention also provides nucleic acid molecules encoding DD, DED and NB-ARC domain proteins, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention DDs, DEDs or NB-ARC domains. Such DDs, DEDs and NB-ARC domains and/or anti-DD, anti-DED or anti-NB-ARC domain antibodies are useful for discovery of drugs that suppress infection, autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases. | 08-18-2011 |
